Emera

Emera Med is a clinical-stage biotechnology company focused on developing treatments for heavy metal toxicity and oxidative stress-related conditions. The company's lead candidate, Emeramide (NBMI), is a lipid-soluble, dithiolic antioxidant and metal chelator designed to safely bind and neutralize toxic metals like mercury. Emeramide has received Orphan Drug Designation from both the FDA and EMA for the treatment of mercury poisoning. Beyond metal detoxification, the company is exploring the compound's potential in treating various chronic inflammatory and neurodegenerative diseases. Emera Med aims to address the limitations of existing chelation therapies by providing a compound that can penetrate cellular membranes and the blood-brain barrier.